SARS-CoV-2

[Blood Cancer Discovery] Researchers analyzed anti-SARS-CoV-2 spike IgG antibody titers and neutralizing Ab among 217 recipients of cellular treatments.

[Nature Medicine] The authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis on anti-CD20 antibody monotherapy compared with healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.

[Nature Microbiology] Researchers determined the structures of two human monoclonal antibodies–AZD8895 and AZD1061–which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain of SARS-CoV-2 to define the genetic and structural basis of neutralization.

[Signal Transduction and Targeted Therapy] Researchers characterized the immune phenotype of B cells from 15 recovered COVID-19 patients, and found that healthy controls and recovered patients had similar B-cell populations before and after BCR stimulation.

[Science Advances] Investigators found that viral infection promoted the G protein–coupled receptor lysophosphatidic acid (LPA)1 expression, and LPA restrained type I/III interferon production through LPA1.

[Nature Communications] Researchers report four nanobodies engineered as homotrimers with pmolar affinity for the receptor binding domain of the SARS-CoV-2 spike protein.